89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 24, 2020 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD’s The Liver Meeting® 2020
November 13, 2020 08:00 ET
|
89bio, Inc.
– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing – – Consistent results and baseline characteristics across biopsy confirmed and...
89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 10, 2020 16:02 ET
|
89bio, Inc.
– Updated clinical data from BIO89-100’s Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting – – Planning to initiate the Phase 2b trial as part of the...
89bio To Present Data From Phase 1b/2a Study of BIO89-100 In NASH at AASLD’s The Liver Meeting® 2020
November 02, 2020 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Present at Upcoming Investor Conference
September 28, 2020 17:18 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Pricing of Upsized Public Offering of Common Stock
September 16, 2020 20:51 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Proposed Public Offering of Common Stock
September 14, 2020 17:21 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
September 14, 2020 07:01 ET
|
89bio, Inc.
All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo Favorable safety and...
89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH
September 13, 2020 19:53 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study...
89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia
September 03, 2020 08:30 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...